Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neuroscience Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CRIPT drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CRIPT Recombinant Protein (Full-Length / Truncated) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CRIPT Products |
| Gene Delivery | CRIPT Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CRIPT Products |
| Benchmark Ab | Anti-CRIPT Recombinant Antibody Recombinant positive control for validation. |
View CRIPT Products |
| Validator | CRIPT siRNA Set For knockdown verification. |
View CRIPT Products |
| Related Target A | DLG4 (PSD-95) Primary binding partner of CRIPT; essential for postsynaptic density scaffolding and downstream signaling. |
View DLG4 Products |
| Related Target B | TUBB (Beta-Tubulin) Interacts with CRIPT to facilitate microtubule bridging and cytoskeletal transport. |
View TUBB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (CRIPT-PSD-95) | High-purity, sequence-verified recombinant CRIPT and DLG4 proteins available with native folding. |
| Intracellular pathway validation & knockdown | Validated siRNA sets and high-titer Lentiviral particles for robust gene knockdown or overexpression. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CRIPT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRIPT therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule protein-protein interaction (PPI) inhibitors and RNA-targeting modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the CRIPT-PSD-95 complex in neurological disorders and its tubulin-binding function in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Institutes, Biotech Startups | Neuropathic Pain, Ischemic Stroke | Selectivity Assay (Need high-purity CRIPT & DLG4 proteins for SPR/FP screening) |
| siRNA / Antisense | RNAi Therapeutics Developers | Glioblastoma, Solid Tumors | Knockdown Validation (Need sequence-verified siRNA & qPCR controls) |
| Peptide Therapeutics | Peptide Drug Discovery Firms | Neurodegenerative Diseases | Binding Affinity (Need endotoxin-controlled, native-like recombinant proteins) |